Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
162
Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

173
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
173

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navepegritide: First Approval.

Drugs·2026
Same author

Pixavir Marboxil: First Approval.

Drugs·2026
Same author

Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Correction: Donanemab: First Approval.

Drugs·2024
Same author

Donanemab: First Approval.

Drugs·2024
Same author

Sotatercept: First Approval.

Drugs·2024

Related Experiment Video

Updated: Jun 29, 2025

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.7K

Danicopan: First Approval.

Connie Kang1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|March 26, 2024
PubMed
Summary
This summary is machine-generated.

Danicopan, a novel complement factor D inhibitor, offers a new oral add-on therapy for paroxysmal nocturnal haemoglobinuria (PNH). It addresses residual haemolysis in patients treated with C5 inhibitors, marking a significant advancement in PNH management.

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
04:01

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis

Published on: September 8, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 29, 2025

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.7K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.1K
Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis
04:01

Indocyanine Green-Guided Intraoperative Imaging to Facilitate Video-Assisted Retroperitoneal Debridement for Treating Acute Necrotizing Pancreatitis

Published on: September 8, 2022

2.4K

Area of Science:

  • Pharmacology
  • Hematology
  • Rare Diseases

Background:

  • Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired blood disorder characterized by complement-mediated intravascular and extravascular haemolysis.
  • Current treatments like C5 inhibitors (eculizumab, ravulizumab) target terminal complement, but some patients experience residual haemolytic anaemia.
  • Extravascular haemolysis, driven by the alternative complement pathway, remains a therapeutic challenge in PNH.

Purpose of the Study:

  • To summarize the development milestones of danicopan, an oral complement factor D inhibitor.
  • To highlight the regulatory approvals of danicopan as an add-on therapy for PNH in Japan and Europe.
  • To discuss the clinical significance of danicopan in managing residual haemolytic anaemia in PNH patients.

Main Methods:

  • Review of clinical development data and regulatory submissions for danicopan.
  • Analysis of danicopan's mechanism of action as a complement factor D inhibitor.
  • Summary of clinical trial outcomes demonstrating efficacy and safety in PNH patients.

Main Results:

  • Danicopan received approval in Japan for adults with PNH on C5 inhibitor therapy.
  • The European Medicines Agency recommended marketing authorization for danicopan in PNH with residual haemolytic anaemia.
  • Danicopan demonstrated efficacy in reducing extravascular haemolysis and improving anaemia in PNH patients.

Conclusions:

  • Danicopan represents a significant therapeutic advancement for PNH patients with residual haemolysis.
  • Its development and approval offer a new oral treatment option targeting the alternative complement pathway.
  • Danicopan's add-on strategy addresses an unmet need in PNH management, improving patient outcomes.